We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GYRE Gyre Therapeutics Inc

0.29 (1.23%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 98,188
Bid Price 22.00
Ask Price 23.81
News -
Day High 25.09


52 Week Range


Day Low 21.70
Company Name Stock Ticker Symbol Market Type
Gyre Therapeutics Inc GYRE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.29 1.23% 23.81 18:42:39
Open Price Low Price High Price Close Price Prev Close
22.52 21.70 25.09 23.40 23.52
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,797 98,188 $ 23.37 $ 2,294,184 - 5.88 - 27.3889
Last Trade Time Type Quantity Stock Price Currency
19:55:59 7 $ 22.51 USD

Gyre Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 60.28M - - - -731.45
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Gyre Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No GYRE Message Board. Create One! See More Posts on GYRE Message Board See More Message Board Posts

Historical GYRE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week17.2127.388916.9522.92249,2826.6038.35%
1 Month6.4027.38896.3217.98128,27917.41272.03%
3 Months7.0027.38895.8817.45116,16816.81240.14%
6 Months7.0027.38895.8817.45116,16816.81240.14%
1 Year7.0027.38895.8817.45116,16816.81240.14%
3 Years7.0027.38895.8817.45116,16816.81240.14%
5 Years7.0027.38895.8817.45116,16816.81240.14%

Gyre Therapeutics Description

Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |